US Stock MarketDetailed Quotes

CCCC C4 Therapeutics

Watchlist
  • 3.180
  • -0.020-0.63%
Close Feb 14 16:00 ET
  • 3.190
  • +0.010+0.31%
Post 19:59 ET
224.47MMarket Cap-1.86P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Jan 14 06:00
    NEWS
    $C4 Therapeutics (CCCC.US)$
    C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology
    Tuesday, 14th January at 7:00 am
    Cemsidomide Data Presented at American Society of Hematology (ASH) Annual Meeting Support Best-in-Class Profile; Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin's Lymphoma
    CFT1946 Phase 1 Trial Continues to Progress in BRAF V600X Solid Tumors With Monoth...
    This_Guy
    This_Guy
    Dec 8, 2024 17:20
    $C4 Therapeutics (CCCC.US)$
    C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
    Positive
    36% overall response rate and 45% clinical benefit rate achieved in MM at highest dose level
    38% overall response rate in NHL across all subtypes
    44% overall response rate in PTCL specifically
    No treatment emergent adverse events leading to dose reduction
    Well-tolerated safety profile...
    Jaguar8
    Jaguar8
    Dec 8, 2024 16:21
    NEWS SUNDAY 12/8
    $C4 Therapeutics (CCCC.US)$
    C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
    C4 Therapeutics (CCCC) presented Phase 1 trial data for cemsidomide at the ASH Annual Meeting, showing promising results in both multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). In MM, cemsidomide with dexamethasone achieved a 36% overall response rate and 45% clinical b...
    Trytosaveabit
    Trytosaveabit
    Dec 8, 2024 15:59
    Watching Monday/week 12/9/24 Data released
    $C4 Therapeutics (CCCC.US)$ In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels
    Multiple Myeloma Arm Demonstrated Well-Tolerated Safety Profile; On-Target Neutropenia Was Manageable With Low Rates of Febrile Neutropenia and Infections; No Treatment Emergent Adverse Events Le...
Read more

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
No. Symbol % Chg
XINGANJIANG
873167
+30.00%
INNOVATIVE DATA
835305
+29.98%
CHENGUANG MEDICAL
430300
+29.96%
4
Hangzhou Gaoxin Materials Technology
300478
+20.04%
5
Beijing Philisense Technology
300287
+20.03%
Log In for the Full List
Unlock Now
Investment Course
Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call
Monetary Policy: Navigating the Fed's Rate Cut Cycle
Changing Fed policy is altering the market math for investors.